Cytori Cell Research Institute, Inc. (TYO:3750)
Japan
· Delayed Price · Currency is JPY 692.00
-6.00 (-0.86%)
May 23, 2025, 3:30 PM JST
TYO:3750 Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Revenue | 122 | 1,560 | 2,144 | 1,335 | 1,388 | Upgrade
|
| Revenue Growth (YoY) | -92.18% | -27.24% | 60.60% | -3.82% | 17.63% | Upgrade
|
| Cost of Revenue | 129 | 268 | 876 | 476 | 628 | Upgrade
|
| Gross Profit | -7 | 1,292 | 1,268 | 859 | 760 | Upgrade
|
| Selling, General & Admin | 549 | 1,506 | 1,783 | 1,085 | 1,268 | Upgrade
|
| Research & Development | 202 | 351 | - | - | - | Upgrade
|
| Operating Expenses | 800 | 2,065 | 2,063 | 1,321 | 1,491 | Upgrade
|
| Operating Income | -807 | -773 | -795 | -462 | -731 | Upgrade
|
| Interest Expense | -82 | -153 | -129 | -93 | -84 | Upgrade
|
| Interest & Investment Income | 3 | -487 | 11 | 19 | 13 | Upgrade
|
| Other Non Operating Income (Expenses) | 25 | 19 | 63 | 137 | 71 | Upgrade
|
| EBT Excluding Unusual Items | -861 | -1,394 | -850 | -399 | -731 | Upgrade
|
| Gain (Loss) on Sale of Investments | -67 | - | -107 | 299 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -51 | 688 | - | - | - | Upgrade
|
| Asset Writedown | -1,173 | -336 | -205 | - | - | Upgrade
|
| Legal Settlements | - | - | - | -3 | - | Upgrade
|
| Other Unusual Items | - | 30 | -3 | 37 | 77 | Upgrade
|
| Pretax Income | -2,152 | -1,012 | -1,165 | -66 | -654 | Upgrade
|
| Income Tax Expense | -12 | -1,150 | -106 | 11 | 121 | Upgrade
|
| Earnings From Continuing Operations | -2,140 | 138 | -1,059 | -77 | -775 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | -56 | Upgrade
|
| Net Income | -2,140 | 138 | -1,059 | -77 | -831 | Upgrade
|
| Net Income to Common | -2,140 | 138 | -1,059 | -77 | -831 | Upgrade
|
| Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 8 | Upgrade
|
| Shares Change (YoY) | -0.34% | 0.34% | 1.12% | 7.89% | 21.93% | Upgrade
|
| EPS (Basic) | -239.69 | 15.46 | -118.61 | -8.72 | -101.53 | Upgrade
|
| EPS (Diluted) | -239.69 | 15.42 | -118.61 | -8.72 | -101.53 | Upgrade
|
| Free Cash Flow | -995 | -1,169 | -197 | -367 | -97 | Upgrade
|
| Free Cash Flow Per Share | -111.44 | -130.49 | -22.06 | -41.56 | -11.85 | Upgrade
|
| Gross Margin | -5.74% | 82.82% | 59.14% | 64.34% | 54.75% | Upgrade
|
| Operating Margin | -661.48% | -49.55% | -37.08% | -34.61% | -52.67% | Upgrade
|
| Profit Margin | -1754.10% | 8.85% | -49.39% | -5.77% | -59.87% | Upgrade
|
| Free Cash Flow Margin | -815.57% | -74.94% | -9.19% | -27.49% | -6.99% | Upgrade
|
| EBITDA | -758 | -520 | -465 | -142 | -425 | Upgrade
|
| EBITDA Margin | - | -33.33% | -21.69% | -10.64% | -30.62% | Upgrade
|
| D&A For EBITDA | 49 | 253 | 330 | 320 | 306 | Upgrade
|
| EBIT | -807 | -773 | -795 | -462 | -731 | Upgrade
|
| EBIT Margin | - | -49.55% | -37.08% | -34.61% | -52.67% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.